Alpha 2.0
Login Register
» Authors » Heidi Friedrichs

Heidi Friedrichs

Explore the profile of Heidi Friedrichs including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 226
Followers 0
Related Specialties
Psychiatry
Molecular Biology
General Medicine
Top 10 Co-Authors
Hannelore Ehrenreich
Sabrina Grube
Martin Begemann
Klaus-Armin Nave
Katja Ribbe
Sergi Papiol
Peter Falkai
Ahmed El-Kordi
Nils Brose
Martin F Gerchen
Published In
Arch Gen Psychiatry
EMBO Mol Med
BMC Psychiatry
Best Pract Res Clin Anaesthesiol
Am J Med Genet B Neuropsychiatr Genet
Affiliations
Soon will be listed here.
Recent Articles
1.
Common variants of the genes encoding erythropoietin and its receptor modulate cognitive performance in schizophrenia
Kastner A, Grube S, El-Kordi A, Stepniak B, Friedrichs H, Sargin D, et al.
Mol Med . 2012 Jun; 18:1029-40. PMID: 22669473
Erythropoietin (EPO) improves cognitive performance in clinical studies and rodent experiments. We hypothesized that an intrinsic role of EPO for cognition exists, with particular relevance in situations of cognitive decline,...
2.
Prediction of the risk of comorbid alcoholism in schizophrenia by interaction of common genetic variants in the corticotropin-releasing factor system
Ribbe K, Ackermann V, Schwitulla J, Begemann M, Papiol S, Grube S, et al.
Arch Gen Psychiatry . 2011 Aug; 68(12):1247-56. PMID: 21810631
Context: Stress plays a major role in the development of comorbid alcohol use disorder (AUD). In turn, AUD worsens the outcome of psychiatric patients with respect to global disease severity,...
3.
Erythropoietin as neuroprotective and neuroregenerative treatment strategy: comprehensive overview of 12 years of preclinical and clinical research
Sargin D, Friedrichs H, El-Kordi A, Ehrenreich H
Best Pract Res Clin Anaesthesiol . 2011 May; 24(4):573-94. PMID: 21619868
Erythropoietin (EPO), originally discovered as hematopoietic growth factor, has direct effects on cells of the nervous system that make it a highly attractive candidate drug for neuroprotection/neuroregeneration. Hardly any other...
4.
A CAG repeat polymorphism of KCNN3 predicts SK3 channel function and cognitive performance in schizophrenia
Grube S, Gerchen M, Adamcio B, Pardo L, Martin S, Malzahn D, et al.
EMBO Mol Med . 2011 Mar; 3(6):309-19. PMID: 21433290
KCNN3, encoding the small conductance calcium-activated potassium channel SK3, harbours a polymorphic CAG repeat in the amino-terminal coding region with yet unproven function. Hypothesizing that KCNN3 genotypes do not influence...
5.
A phenotype-based genetic association study reveals the contribution of neuregulin1 gene variants to age of onset and positive symptom severity in schizophrenia
Papiol S, Begemann M, Rosenberger A, Friedrichs H, Ribbe K, Grube S, et al.
Am J Med Genet B Neuropsychiatr Genet . 2011 Jan; 156B(3):340-5. PMID: 21234898
By pure endpoint diagnosis of the disease, the risk of developing schizophrenia has been repeatedly associated with specific variants of the neuregulin1 (NRG1) gene. However, the role of NRG1 in...
6.
The cross-sectional GRAS sample: a comprehensive phenotypical data collection of schizophrenic patients
Ribbe K, Friedrichs H, Begemann M, Grube S, Papiol S, Kastner A, et al.
BMC Psychiatry . 2010 Nov; 10:91. PMID: 21067598
Background: Schizophrenia is the collective term for an exclusively clinically diagnosed, heterogeneous group of mental disorders with still obscure biological roots. Based on the assumption that valuable information about relevant...
7.
Modification of cognitive performance in schizophrenia by complexin 2 gene polymorphisms
Begemann M, Grube S, Papiol S, Malzahn D, Krampe H, Ribbe K, et al.
Arch Gen Psychiatry . 2010 Sep; 67(9):879-88. PMID: 20819981
Context: Schizophrenia is the collective term for a heterogeneous group of mental disorders with a still obscure biological basis. In particular, the specific contribution of risk or candidate gene variants...